The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2023 | Selecting conditioning regimens for patients with myelofibrosis undergoing alloSCT
Wael Saber, MD, MS, Froedtert & Medical College of Wisconsin, Milwaukee, WI, discusses a study analyzing the choice of conditioning regimen for patients with myelofibrosis (MF) undergoing allogeneic stem cell transplantation (alloSCT), and which are optimal. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
